C
Craig B. H. Surman
Researcher at Harvard University
Publications - 74
Citations - 3191
Craig B. H. Surman is an academic researcher from Harvard University. The author has contributed to research in topics: Attention deficit hyperactivity disorder & Randomized controlled trial. The author has an hindex of 29, co-authored 69 publications receiving 2886 citations. Previous affiliations of Craig B. H. Surman include Partners HealthCare.
Papers
More filters
Journal ArticleDOI
A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
Thomas J. Spencer,Joseph Biederman,Timothy E. Wilens,Robert Doyle,Craig B. H. Surman,Jefferson B. Prince,Eric Mick,Megan Aleardi,Kathleen Herzig,Stephen V. Faraone +9 more
TL;DR: A marked therapeutic response for the MPH treatment of ADHD symptoms that exceeded the placebo response was found and robust doses of MPH are effective in the treatment of adult ADHD.
Journal ArticleDOI
Cognitive Behavioral Therapy vs Relaxation With Educational Support for Medication-Treated Adults With ADHD and Persistent Symptoms: A Randomized Controlled Trial
Steven A. Safren,Susan Sprich,Matthew J. Mimiaga,Craig B. H. Surman,Laura E. Knouse,Meghan Groves,Michael W. Otto +6 more
TL;DR: Among adults with persistent ADHD symptoms treated with medication, the use of cognitive behavioral therapy compared with relaxation with educational support resulted in improved ADHD symptoms, which were maintained at 12 months.
Journal ArticleDOI
A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Joseph Biederman,Eric Mick,Craig B. H. Surman,Robert Doyle,Paul Hammerness,Theresa Harpold,Stephanie Dunkel,Meghan Dougherty,Megan Aleardi,Thomas J. Spencer +9 more
TL;DR: Treatment with OROS MPH in daily doses of up to 1.3 mg/kg/day was effective in the treatment of adults with ADHD, and was associated with clinically and statistically significant reductions in DSM-IV symptoms of inattention and hyperactivity/impulsivity.
Journal ArticleDOI
Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.
George Bush,Thomas J. Spencer,Jennifer Holmes,Lisa M. Shin,Eve M. Valera,Larry J. Seidman,Nikos Makris,Craig B. H. Surman,Megan Aleardi,Eric Mick,Joseph Biederman +10 more
TL;DR: Methylphenidate OROS increased daMCC activation during the MSIT and may act, in part, by normalizing daMcc hypofunction in ADHD.
Journal ArticleDOI
Are girls with ADHD at risk for eating disorders? Results from a controlled, five-year prospective study.
Joseph Biederman,Sarah W. Ball,Michael C. Monuteaux,Craig B. H. Surman,Jessica L. Johnson,Sarah Zeitlin +5 more
TL;DR: The presence of an eating disorder in girls with ADHD heightens the risk of additional morbidity and dysfunction, and the incidence of lifetime eating disorders in a large adolescent population of girls with and without ADHD is estimated.